Johnson and Johnson successfully applied for a patent extension on bedaquiline; however, in a big win for LMI countries, the company has decided not to enforce its patent, allowing generic producers to manufacture the drug. Additionally, J&J has reduced the price of bedaquiline for South Africa by around 40%, making it more affordable for the country. J&J’s reversal of its past decisions regarding bedaquiline was prompted by an investigation of the company’s pricing policies led by the South African government. Learn more here.
top of page
Recent Posts
See AllPhumeza Tisile was treated for MDR-TB in 2010 and suffered severe side effects from the drug, kanamycin. Her experiences drove her to...
120
The WHO has released new guidelines for prophylactic TB treatments. Among the updates to the guidelines are adjusted dosage...
100
The TB-CAPT consortium released a new study recently that showed that the new Xpert MTB/XDR testing can provide signigificantly faster...
170
bottom of page
Comments